^
Association details:
Biomarker:IRS2 amplification
Cancer:Colorectal Cancer
Drug:BMS-754807 (IGF-1R inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines

Excerpt:
In addition, the cell lines with KRAS mutations, those with either insulin receptor substrate 2 (IRS2) copy number gain (CNG) or higher IGF-1R expression levels, were more sensitive to the drug.
DOI:
10.1158/1535-7163.MCT-14-0794-T